Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) Operating Margin (2016 - 2025)

Sonoma Pharmaceuticals has reported Operating Margin over the past 16 years, most recently at 15.59% for Q4 2025.

  • For Q4 2025, Operating Margin rose 1334.0% year-over-year to 15.59%; the TTM value through Dec 2025 reached 15.61%, up 1633.0%, while the annual FY2025 figure was 25.97%, 1095.0% up from the prior year.
  • Operating Margin for Q4 2025 was 15.59% at Sonoma Pharmaceuticals, down from 6.01% in the prior quarter.
  • Over five years, Operating Margin peaked at 6.01% in Q3 2025 and troughed at 133.16% in Q1 2022.
  • A 5-year average of 39.63% and a median of 28.1% in 2024 define the central range for Operating Margin.
  • Biggest five-year swings in Operating Margin: plummeted -5569bps in 2021 and later skyrocketed 9510bps in 2023.
  • Year by year, Operating Margin stood at 33.01% in 2021, then crashed by -89bps to 62.3% in 2022, then soared by 57bps to 26.9% in 2023, then decreased by -8bps to 28.93% in 2024, then soared by 46bps to 15.59% in 2025.
  • Business Quant data shows Operating Margin for SNOA at 15.59% in Q4 2025, 6.01% in Q3 2025, and 27.27% in Q2 2025.